Treatment for non-Hodgkin's lymphoma in relapse: what are the alternatives?
Article Abstract:
The most effective treatment for relapsing non-Hodgkin's lymphoma is aggressive chemotherapy and transplantation with one's own bone marrow, however treatment must still be improved and extended to more people. A 1995 study found that aggressive chemotherapy plus autologous bone marrow transplantation was better than chemotherapy alone in improving the survival of patients with recurrent non-Hodgkin's lymphoma. However, the study also showed that many people with this disease are resistant to chemotherapy and may not respond to any treatment. In general, treating this disease involves first establishing that the disease is recurring and then choosing between various powerful chemotherapy combinations. New techniques in treating relapses include using monoclonal antibodies and continuous, low doses of chemotherapy. Treatments have also been improved by using cells that give rise to blood cells and growth factors.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Treatment of non-Hodgkin's lymphoma
Article Abstract:
Recent advancements have improved the treatment of patients with different forms of non-Hodgkin's lymphoma. Non-Hodgkin's lymphoma includes different types of cancer of the lymph and reticuloendothelial systems. Diagnosis of patients with suspected non-Hodgkin's lymphoma should be based on evaluation of a biopsy specimen by a hematopathologist. A formulation has been developed for classification of different types of non-Hodgkin's lymphoma. Patients who are likely to respond to treatment may be identified by a stage evaluation. Non-Hodgkin's lymphoma patients who are at risk for a relapse may also be identified through evaluation of genetic abnormalities. The treatment program for patients with non-Hodgkin's lymphoma should take into consideration a variety of factors. Most patients undergo chemotherapy with or without radiation therapy.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1993
User Contributions:
Comment about this article or add new information about this topic:
Radioimmunotherapy of B-cell lymphoma with /131I~anti-B1 (anti-CD20) antibody
Article Abstract:
Radioimmunotherapy may be an effective treatment for B-cell lymphoma. This type of treatment involves the use of radioisotope-labeled antibodies that attack cancer cells and leave normal cells alone. Ten patients with B-cell lymphoma were treated intravenously with anti-B cell monoclonal antibodies labeled with 131I, a radioisotope of iodine, at one week intervals. After the first course of treatment, nine patients were pretreated with unlabeled antibodies to increase the delivery of radioactivity to cancer cells. Of the nine patients who were pretreated, six responded to treatment. Four patients went into complete remission. Three of these patients remained in complete remission, and one was in remission for eight months. The two other patients who responded to treatment went into partial remission.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1993
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Growing old in Greece. Do exposes of poor care really put patients first?
- Abstracts: The incidence of orofacial injuries in sports: a pilot study in Illinois. Orofacial lipomas diagnosed by CT and MRI
- Abstracts: At home with stoma care. Oh, what a lovely stoma. Choice cuts: the growth of sponsored stoma-care nurses is proving an increasing threat to services offered by the NHS
- Abstracts: How to grow more leaders. Throwing a good book at doctors
- Abstracts: Holiday blues: don't let the crush of the season get you down. Hostility and your heart: can your personality make you sick?
what the better thr radiation or chemo